{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-24-000041","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.123458+00:00","generated_at":"2026-06-04T07:56:34.064434+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Praxis reports 100% response rate in PRAX-628 Phase 2a epilepsy PPR study; plans focal onset trial H2 2024","bullets":["15 mg cohort: 100% total response (20% partial, 80% complete); 45 mg cohort: 100% complete response.","Combined cohort: 88% complete response, 12% partial response; 8 of 9 evaluable patients responded.","Safety consistent with Phase 1; pharmacokinetic analysis confirmed therapeutic exposures.","Company plans to initiate a focal onset epilepsy efficacy study in second half of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-24-000041","json":"https://secwatch.observer/filing/0001689548-24-000041.json","markdown":"https://secwatch.observer/filing/0001689548-24-000041.md","text":"https://secwatch.observer/filing/0001689548-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000041/0001689548-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954824000041/prax-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:56:34.064434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}